
Feature|Videos|June 25, 2025
Navigating Regulatory Barriers within Market Access
A panel of industry leaders emphasize the importance of early engagement with payers, real-world evidence, and value-based endpoints to ensure successful access, pricing, and long-term market viability—especially in a more complex, globally integrated reimbursement landscape.
Advertisement
Episodes in this series

As international price referencing tightens and payer expectations rise, companies face a shrinking margin for error. The panel explores how clinical trial design and early payer engagement are key to meeting both regulatory and reimbursement demands across global markets. With real-world evidence (RWE) from markets like Korea and Japan in hand, forward-thinking strategies can prove valuable.
Key discussion topics include:
- Navigating international price referencing and fragmented regulatory standards.
- Why payer engagement should begin as early as clinical trial design.
- RWE as a tool for value messaging in global markets.
- The diminishing threat of generics for advanced therapies like cell therapy.
Advertisement
Related to this article

Sanofi is exploring a $35B–$43B takeover of Insmed and its blockbuster lung drug Brinsupri as the French pharma giant braces for Dupixent’s looming patent expiration.

Innogen grants Arcera exclusive rights to its long-acting GLP-1 receptor agonist across Africa, Eastern Europe, Latin America and the Middle East.

With rising healthcare costs, practices are embracing flexible payment models and upfront pricing transparency to keep care accessible.

Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed four times a year.

Novartis narrowed its mid-term sales growth outlook to 5% annually through 2031 at its London investor day, as patent expirations weigh on the Swiss drugmaker.

DISCO Pharmaceuticals gets $40M upfront from AbbVie and could earn up to $2.5B in milestones to develop AND-gated bispecifics for solid tumors.
Advertisement
Advertisement
Trending on PharmExec
1
Sanofi Eyes Insmed in Potential $43B Deal as Dupixent Patent Clock Ticks
2
Innogen Licenses GLP-1 Therapy Efsubaglutide Alfa to Arcera
3
FDA Approves Livsayis, Regeneron's First siRNA Therapy for Myasthenia Gravis
4
DISCO, AbbVie Sign AND-Gated Bispecific Deal Worth Up to $2.5B
5


